Canada · Delayed Price · Currency is CAD Appili Therapeutics Company Description
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of treatments targeting unmet needs in infectious diseases in the United States and Canada.
The company offers LIKMEZ (ATI-1501), a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial and protozoal infections.
It also develops ATI-1801, a topical formulation of paromomycin in a Phase III trial for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine in preclinical trials for the prevention of Francisella tularensis infection.
The company has a collaboration with Vitalex Biosciences to advance VXV-01, a dual-antigen vaccine targeting invasive Candida infections.
Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.
| Country | Canada |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Donald Cilla |
Contact Details
Address: 1344 Summer Street Halifax, NS B3H 0A8 Canada | |
| Phone | 902-442-4655 |
| Website | appilitherapeutics.com |
Stock Details
| Ticker Symbol | APLI |
| Exchange | Toronto Stock Exchange |
| Share Class | Class A Shares |
| Fiscal Year | April - March |
| Reporting Currency | CAD |
| ISIN Number | CA03783R1073 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Donald D. Cilla Jr., M.B.A., Pharmd | Chief Executive Officer, President and Director |
| Kenneth G. Howling | Acting Chief Financial Officer |
| Dr. Gary S. Nabors Ph.D. | Chief Development Officer |
| Dr. Carl Gelhaus Ph.D. | Director of Non-Clinical Research |
| Arthur Baran | Director of New Product Development |
| Jenna McNeil | Corporate Affairs and Communications Manager |